» Articles » PMID: 34017536

Malat-1 Expression in Bladder Carcinoma Tissues and Its Clinical Significance

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2021 May 21
PMID 34017536
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the expression of metastasis-associated lung adenocarcinoma transcript 1 (Malat-1) in bladder carcinoma and its relationship with clinicopathological characteristics and prognosis.

Methods: Specimens were collected from 90 patients with bladder carcinoma who underwent urological surgery in our hospital. Twenty patients diagnosed with benign prostatic hyperplasia were selected as the negative control. The expression of Malat-1 was detected by real-time reverse transcription PCR, and its relationship with clinicopathological factors and prognosis was analyzed.

Results: The expression of Malat-1 in bladder carcinoma tissues (2.55±0.31) was higher than that in adjacent tissues (1.62±0.42) and normal bladder mucosa tissues (0.84±0.06); the differences were statistically significant (t=13.647 and 27.302, both P<0.001). The high expression rate of Malat-1 in bladder carcinoma tissues (86.67%) was significantly higher than that in adjacent tissues (22.22%) and normal bladder mucosa tissues (5.00%; P=0.000 and 0.000). The high expression rate of Malat-1 was correlated with age, tumor staging, degree of differentiation and lymph node metastasis (P=0.018, 0.000, 0.000, and 0.000). The median survival time and the 1-year, 3-year and 5-year survival rates of patients with high Malat-1 expression were lower than those with low expression of Malat-1 (P=0.006, 0.011, 0.000 and 0.002). High expression of Malat-1 is an independent risk factor for poor overall survival (OS) in bladder cancer patients.

Conclusion: Overexpression of Malat-1 in bladder carcinoma tissues is associated with malignant biological characteristics and poor prognosis of patients.

Citing Articles

Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

Jaszek N, Bogdanowicz A, Siwiec J, Starownik R, Kwasniewski W, Mlak R J Clin Med. 2024; 13(23).

PMID: 39685620 PMC: 11642161. DOI: 10.3390/jcm13237159.


LncRNA MALAT1 as diagnostic and prognostic biomarker in colorectal cancers: A systematic review and meta-analysis.

Masrour M, Khanmohammadi S, Habibzadeh A, Fallahtafti P PLoS One. 2024; 19(10):e0308009.

PMID: 39471147 PMC: 11521308. DOI: 10.1371/journal.pone.0308009.


The functions of long non-coding RNA (lncRNA)-MALAT-1 in the pathogenesis of renal cell carcinoma.

Anbiyaee O, Moalemnia A, Ghaedrahmati F, Khombi Shooshtari M, Khoshnam S, Kempisty B BMC Nephrol. 2023; 24(1):380.

PMID: 38124072 PMC: 10731893. DOI: 10.1186/s12882-023-03438-1.


Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer.

Tantray I, Ojha R, Sharma A Front Genet. 2023; 13:1051762.

PMID: 36685879 PMC: 9845264. DOI: 10.3389/fgene.2022.1051762.


Long Non-coding RNA MALAT1: A Key Player in Liver Diseases.

Lu J, Guo J, Liu J, Mao X, Xu K Front Med (Lausanne). 2022; 8:734643.

PMID: 35145971 PMC: 8821149. DOI: 10.3389/fmed.2021.734643.

References
1.
Yang L, Bai H, Deng Y, Fan L . High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur Rev Med Pharmacol Sci. 2015; 19(17):3187-93. View

2.
Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F . Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013; 190(6):2278-87. DOI: 10.1016/j.juro.2013.07.001. View

3.
Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z . Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014; 111(4):736-48. PMC: 4134507. DOI: 10.1038/bjc.2014.383. View

4.
Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G . Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015; 8(5):4881-91. PMC: 4503053. View

5.
Roslan N, Makpol S, Mohd Yusof Y . A Review on Dietary Intervention in Obesity Associated Colon Cancer. Asian Pac J Cancer Prev. 2019; 20(5):1309-1319. PMC: 6857900. DOI: 10.31557/APJCP.2019.20.5.1309. View